ProQR Therapeutics Set to Showcase Innovations in RNA Editing
ProQR Therapeutics Set to Showcase Innovations in RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass. — ProQR Therapeutics NV (NASDAQ: PRQR) has exciting news for the scientific community. Dedicated to transforming lives through innovative RNA therapies, the company is poised to present groundbreaking findings at two upcoming scientific conferences, including the American Society of Gene & Cell Therapy's (ASGCT) 28th Annual Meeting and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference.
Details About the Conferences
The ASGCT meeting is scheduled for May 13-17 in New Orleans, where ProQR will showcase its advanced Axiomer™ RNA editing technology. This platform is vital in the company’s mission to build a comprehensive and diverse pipeline of RNA editing therapies, which aim to deliver significant benefits for patients with various diseases.
Gerard Platenburg, Chief Scientific Officer at ProQR, expressed enthusiasm, stating, "We are eager to share our findings and highlight the versatility of our Axiomer RNA editing technology." ProQR’s participation in these conferences underscores its commitment to advancing innovative therapies and addressing critical medical needs.
ASGCT 28th Annual Meeting Highlights
ProQR's schedule at the ASGCT includes both oral and poster presentations that delve into the scientific advancements facilitated by their technology. Noteworthy topics include:
- Oral Presentation: ADAR-Mediated RNA Editing of SLC10A1(NTCP) as a Therapeutic Approach to Reduce Liver Bile Acid Re-Uptake in Cholestatic Diseases (abstract 333). Presenter: Gerard Platenburg Date/Time: May 16, 2025, 4:15 PM CT Session: Oligonucleotide Therapeutics II
- Poster Presentation: ADAR-Mediated RNA Editing-Based Correction of PNPLA3 I148M Functionality to Address Hepatic Steatosis (abstract 1654). Presenter: Gerard Platenburg Date/Time: May 15, 2025, 5:30-7:00 PM CT Poster Number: AMA1324
- Poster Presentation: ADAR-Mediated RNA Editing of Premature Termination Codon Results in Functional Correction in MECP2 for Rett Syndrome (abstract 1645). Presenter: Gerard Platenburg Date/Time: May 15, 2025, 5:30-7:00 PM CT Poster Number: AMA1427
TIDES USA 2025 Conference Overview
Following ASGCT, ProQR will participate in TIDES USA from May 19-22 in San Diego, where they will further discuss the advancements in oligonucleotide and peptide therapeutics. Key details include:
- Podium Presentation: Advancing Axiomer ADAR RNA Editing Platform - Editing oligonucleotides optimization for therapeutic use. Presenter: Peter A. Beal, PhD, Chief ADAR Scientist Date/Time: May 22, 2025, 2:00 PM PST Session/Track: Genome Editing Technology and Applications
A Glimpse into Axiomer™ Technology
Axiomer™ signifies a leap forward in RNA base editing technology. Designed to create a new class of transformative medicines, Axiomer enables precise single nucleotide changes to RNA with the help of ADAR (Adenosine Deaminase Acting on RNA), which naturally occurs in human cells. This functionality not only allows for the correction of disease-causing mutations but also provides opportunities to modulate protein expression and develop innovative therapeutic solutions.
About ProQR Therapeutics
At the heart of ProQR’s mission is the dedication to develop RNA therapies that can change lives. With a unique focus on addressing both rare and common diseases, ProQR’s Axiomer™ platform is central to the company's growth and the expanding pipeline of RNA-editing therapeutics. By harnessing the body’s innate capabilities, ProQR aims to offer innovative treatments to those in desperate need.
For further insights into ProQR's endeavors, please visit www.proqr.com where they’ll provide access to presentation materials following the conferences.
Frequently Asked Questions
What is ProQR Therapeutics known for?
ProQR Therapeutics is known for its cutting-edge RNA therapies, particularly its proprietary Axiomer™ platform that enables RNA editing to address various diseases.
When and where will ProQR present its findings?
ProQR will present at the ASGCT meeting from May 13-17 in New Orleans and at TIDES USA 2025 from May 19-22 in San Diego.
Who is the Chief Scientific Officer of ProQR?
Gerard Platenburg is the Chief Scientific Officer of ProQR and will be one of the key presenters at both conferences.
What kind of presentations will ProQR be showcasing?
ProQR will showcase oral and poster presentations focusing on its Axiomer RNA editing technology and specific drug applications.
Where can I find more information after the conferences?
Presentation materials will be made available on ProQR's official website following the conferences.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.